GAINESVILLE, Fla., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a sixth U.S. patent for its novel, non-leaching NIMBUS® antimicrobial technology.
The U.S. Patent and Trademark Office has issued Quick-Med Technologies U.S. Patent No. 8,088,400 entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers." The new patent covers the Company's novel polyurethane-modified polycation, the newest member of the NIMBUS technology family of antimicrobials. NIMBUS technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation which is built into the backbone of various polymers such as polyurethane in this case.
The newly granted patent is a key "composition-of-matter" patent that covers incorporation of a NIMBUS polycation into main chain of a urethane polymer. The physical state of the polyurethane polycation can be modified to alter the strength of the antimicrobial, the breathability of the film or coating and its flexibility or rigidity. The patent provides protection for various claims regarding the efficacy and durability of an antimicrobial polyurethane.
"This patent adds an exciting new dimension to our NIMBUS technology," says Dr. William Toreki, co-inventor and Quick-Med's Chief Chemist. "Our new polyurethane polycation is well suited for a wide range of applications including films and coatings, adhesives, catheters and other types of extruded tubing, and as a durable hand sanitizer."
"This sixth NIMBUS patent is strategically important because it significantly expands our proprietary NIMBUS technology," said Dr. Jerry Olderman, Quick-Med's vice president of Research & Development and a co-inventor. "It protects the underlying chemistry for several of our cutting-edge developments including applications for advanced wound dressings, medical adhesives, and catheters."
NIMBUS technology employs a safe, eco-friendly active agent that remains in full concentration on any of several substrates. It controls a broad range of both Gram-positive and Gram-negative bacteria. NIMBUS antimicrobials are not depleted in use, maintain effectiveness even in the presence of large amounts of blood or body fluids, and by design, pose no risk of bacteria developing resistance.
NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is available in the BIOGUARD® barrier dressings from Derma Sciences, Inc. (Nasdaq:DSCI). NIMBUS is the only non-leaching antimicrobial wound dressing. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the healthcare and consumer markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, Stay Fresh® and MultiStat® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. BIOGUARD® is a registered trademark of Derma Sciences, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies Jerry Olderman, Ph.D., VP, R&D (888) 835.2211 Ext 104 firstname.lastname@example.org Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 email@example.com